证券代码：002424 证券简称：ST百灵 公告编号：2025-021 贵州百灵企业集团制药股份有限公司 关于第六届董事会第十六次会议决议的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假 记载、误导性陈述或者重大遗漏。 一、会议召开情况 1、贵州百灵企业集团制药股份有限公司（以下简称"公司"）第 六届董事会第十六次会议由公司董事长姜伟先生召集，会议通知于 2025年4月18日以专人送达、电子邮件、电话等通讯方式发出。 2、本次董事会于2025年4月29日上午10:00在公司三楼会议室以 现场结合通讯方式召开。 3、本次董事会应参会表决董事共9人，实际参会表决的董事9人。 其中独立董事胡坚、晏国菀、杨明、张洪武以通讯方式进行表决。 4、本次董事会由董事长姜伟先生主持，公司监事和高级管理人 员列席了本次董事会。 经现场及通讯投票表决，会议审议通过了以下议案： 议案一、审议通过《2025年第一季度报告》。 关于《2025年第一季度报告》详见公司指定信息披露媒体《证券 时报》《证券日报》《中国证券报》《上海证券报》及巨潮资讯网 （http://www.cninfo.com.cn）。 该议案中 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥760,588,639.34, a decrease of 42.93% compared to ¥1,332,744,270.05 in the same period last year[5] - Net profit attributable to shareholders was ¥24,169,730.06, down 53.25% from ¥51,695,103.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥1,595,976.79, a significant decline of 96.42% compared to ¥44,605,736.36 in the previous year[5] - Basic and diluted earnings per share were both ¥0.02, reflecting a 50.00% decrease from ¥0.04 in the previous year[5] - Net profit for the current period is ¥24,305,694.00, representing a decline of 52.4% from ¥51,074,838.51 in the previous period[18] - Earnings per share (basic and diluted) is ¥0.02, down from ¥0.04 in the previous period[19] Cash Flow - The net cash flow from operating activities improved to ¥102,624,994.29, a 140.30% increase from a negative cash flow of ¥254,664,208.38 in the same period last year[5] - The net cash flow from operating activities was $102.62 million, a significant improvement compared to a net outflow of $254.66 million in the previous period[21] - Total cash outflow from operating activities amounted to $662.47 million, down from $1.04 billion year-over-year[21] - Cash inflow from financing activities was $619.20 million, compared to $541.07 million in the previous period[21] - Cash outflow for employee compensation was $148.98 million, a decrease from $175.70 million year-over-year[21] - Cash paid for taxes was $78.34 million, down from $114.61 million in the previous period[21] - Cash paid for other operating activities was $252.89 million, reduced from $388.93 million year-over-year[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,055,820,136.30, a decrease of 1.11% from ¥7,134,925,658.08 at the end of the previous year[5] - Total current liabilities decreased to ¥3,590,445,962.43 from ¥3,799,824,847.07, a reduction of about 5.5%[14] - Total liabilities amount to ¥3,832,313,151.24, a decrease from ¥3,935,723,314.43 in the previous period[15] - Total non-current assets are valued at ¥3,470,342,343.27, down from ¥3,491,289,386.18, a decrease of approximately 0.6%[14] Research and Development - The company's R&D expenses increased by 168.83% to ¥8,118,990.09, compared to ¥3,020,082.42 in the same period last year, indicating a focus on innovation[8] - Research and development expenses increased to ¥8,118,990.09, up 168.5% from ¥3,020,082.42 in the previous period[18] Shareholder Information - The total number of common shareholders at the end of the reporting period is 80,863[10] - The largest shareholder, Jiang Wei, holds 17.55% of shares, with 245,346,284 shares pledged[10] - The company has a total of 32,588,712 shares held in the repurchase special account, representing 2.33% of total shares[11] - The company has not reported any significant changes in the top 10 shareholders due to margin trading or lending of shares[11] Other Income and Expenses - Other income surged by 672.31% to ¥35,739,844.30, up from ¥4,627,661.00 year-on-year, primarily due to increased government subsidies received by subsidiaries[8] - The company reported a net loss from investment of ¥7,736,280.49, compared to a loss of ¥5,833,183.59 in the previous period[18] - Cash inflow from operating activities totaled ¥765,095,329.13, slightly down from ¥783,207,961.75 last year[20] Accounting and Auditing - The company did not undergo an audit for the first quarter report[22] - The company plans to implement new accounting standards starting in 2025[22]

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. reported a revenue of 3.825 billion yuan and achieved a net profit of 33.62 million yuan in 2024, marking a turnaround from losses [1] Group 1: Financial Performance - The company achieved a revenue of 3.825 billion yuan in 2024, indicating a significant recovery in financial performance [1] - The net profit for the year was 33.62 million yuan, showcasing a successful turnaround from previous losses [1] Group 2: Product Portfolio and Market Position - Guizhou BaiLing's product lineup includes proprietary traditional Chinese medicine (TCM) products such as Yindan Xinnaotong Soft Capsules and Kesu Ting Syrup, which are key revenue drivers [2] - The company’s main products address various health issues, including cardiovascular diseases and respiratory conditions, with Yindan Xinnaotong Soft Capsules serving over tens of millions of patients and generating annual sales of 1.5 billion yuan [2] - The sales of the compound Yizhi Huanghua Spray have exceeded 100 million yuan in major markets, and the product has applied for TCM variety protection [2] Group 3: Marketing and Distribution Strategy - The company has reformed its marketing model and completed direct sales adjustments in 15 provinces, enhancing its distribution capabilities [3] - A new pharmaceutical logistics park has opened, supporting an annual circulation demand of 5 billion yuan for drugs and medical devices, strengthening the company's supply chain [3] Group 4: Research and Development - Guizhou BaiLing is entering a new phase of drug development, with key projects like Tangning Tongluo Tablets entering phase III clinical trials, marking a significant milestone for TCM [4] - The company has several innovative products in the pipeline, including Huanglian Jiedu Pills, which have completed phase III trials and are nearing market approval [4] - Other projects such as BD-77 and Shaoling Pian are expected to launch in the next 1-2 years, potentially leading to a surge in new product offerings [4]

Core Insights - The traditional Chinese medicine (TCM) industry is undergoing significant adjustments due to policy changes, intensified market competition, and inventory buildup, leading to negative growth in revenue and net profit for the Chinese patent medicine sector in 2024 [1][2] - Guizhou Bailing has established a strong brand presence, with its products covering key therapeutic areas and achieving substantial sales, including over 1 billion yuan in sales for its compound Yizhi Huanghua spray [1][2] - Guizhou Bailing is entering a new phase of drug development, with key projects like Tangning Tongluo tablets advancing to Phase III clinical trials, indicating a faster pace for new drug approvals [1][2][4] Company Performance - In 2024, Guizhou Bailing reported total revenue of 3.825 billion yuan and a net profit of 33.62 million yuan, marking a turnaround from previous losses [4] - The company has received a clean internal control audit report, confirming effective financial reporting controls as of December 31, 2024 [4] Market Outlook - The TCM industry is expected to see a turning point in 2025, supported by new policies aimed at enhancing quality and promoting high-quality development in the TCM sector [2] - Companies with strong innovation capabilities and a rich product pipeline are likely to benefit in the long term as the market stabilizes [2]

证券代码：002424 证券简称：ST百灵 公告编号：2025-016 贵州百灵企业集团制药股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚 假记载、误导性陈述或者重大遗漏。 贵州百灵企业集团制药股份有限公司（以下简称"公司"）第六届董事会第 十五次会议于2025年4月28日召开，会议审议通过了《关于会计政策变更的议案》， 根据中华人民共和国财政部（以下简称"财政部"）的最新规定对公司会计政策 进行相应变更。本次会计政策变更事项无须提交公司股东大会审议，相关会计政 策变更的具体情况如下： 一、本次会计政策变更情况 1、变更的原因 根据2023年10月25日财政部发布的《关于印发<企业会计准则解释第17号> 的通知》（财会【2023】21号）的规定，"关于流动负债与非流动负债的划分"、 "关于供应商融资安排的披露"、"关于售后租回交易的会计处理"的内容，自 2024年1月1日起施行。 根据2024年12月6日财政部发布的《关于印发<企业会计准则解释第18号>的 通知》（财会【2024】24 号）的规定，"关于不属于单项履约义务的保证类质 量保证的会计处理"的 ...

贵州百灵企业集团制药股份有限公司 关于对会计师事务所 2024 年度履职情况的评估报告 贵州百灵企业集团制药股份有限公司（以下简称"公司"）聘请天健会计师 事务所（特殊普通合伙）（以下简称"天健会计师事务所"）作为公司 2024 年年 报审计及内部控制审计机构。根据财政部、国资委及中国证监会颁布的《国有企 业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监管 指引第 1 号——主板上市公司规范运作》和《公司章程》等要求，公司对天健 会计师事务所 2024 年审计过程中的履职情况进行评估，具体情况如下： 1、基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 年 月 18 日 组织形式 | 7 | | | 特殊普通合伙 | | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | | | | | 首席合伙人 | 钟建国 上年末合伙人数量 | | | | 241 | 人 | | | 上年末执业人 | ...

贵州百灵企业集团制药股份有限公司 2024 年度监事会工作报告 贵州百灵企业集团制药股份有限公司监事会在股东会的领导下， 按照中华人民共和国《公司法》《证券法》及中国证监会及深交所有 关法律、法规的相关规定，紧紧围绕公司的经营工作，认真履行监督 职责，在促进公司快速发展的同时，维护了股东和公司的合法权益。 一、2024 年公司监事会工作情况 （一）监事会会议召开情况 | 监事会届次 | | | 召开时间 | | | 审议通过的议案 | | --- | --- | --- | --- | --- | --- | --- | | 第六届监事会第四次会议 | 2024 | 年 | 2 月 | 29 | 日 | 1、《监事会议事规则》。 | | 第六届监事会第五次会议 | 2024 | 年 | 4 月 | 16 | 日 | 1、《关于变更回购股份用途并注销 | | | | | | | | 的议案》。 | | | | | | | | 1、《2023 年度监事会工作报告》； | | | | | | | | 2、《2023 年年度报告及摘要》； | | | | | | | | 3、《关于募集资金年度存放与使用 | | | ...

证券代码：002424 证券简称：ST 百灵 公告编号：2025-018 贵州百灵企业集团制药股份有限公司 关于募集资金年度存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容真实、准确和完整，公告不存在虚假记载、误导 性陈述或者重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理 和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发 的《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1145 号）的规定，将本公司募集资金 2024 年度存放与使用情 况专项说明如下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可〔2010〕629 号文核准，并经深圳证券交易所同意， 本公司由主承销商宏源证券股份有限公司（现已更名为：申万宏源证券承销保荐有限责任公 司，以下简称宏源证券公司）采用网下询价配售与网上向社会公众投资者定价发行相结合方 式，向社会公众公开发行人民币普通股（A 股）股票 3,700 万股，发行价为 ...